YOU ARE A LEADING PLAYER IN THE NUTRACEUTICAL MARKET

Transcription

1

2 YOU ARE A LEADING PLAYER IN THE NUTRACEUTICAL MARKET LOOKING FOR? Fast innovation Significant growth Superior and scientifically-proven performances Unbeatable product safety

3 SELECT KIONUTRIME-CSG And you will be at the forefront of competition! The RIGHT ingredient to boost your business thanks to its unique features : Superior fat-binding capacity: bind at least 800 times its own weight in fat in vitro Generally Recognized as Safe (GRAS) pursuant to 21 CFR Positive opinion related to maintenance of LDL-cholesterol issued by the EFSA High purity ingredient Odorless & tasteless Appropriate for use in Kosher, Halal and vegetarian products The lowest dose needed: 1.5g/day Safe and non allergenic : 100% animal-free, GMO-free, allergen-free

4 KIONUTRIME-CSG IS SUITABLE FOR WEIGHT MANAGEMENT Binds at least 800 times its own weight in fat Binds up to 29% of dietary fats Prevents weight and fat gain Intestinal bulk enriched in lipids Induced satiety FOR CHOLESTEROL MANAGEMENT Positive health claim issued by EFSA related to chitosan and maintenance of normal blood LDL-cholesterol FORMEDICAL DEVICE Due to its mechanism of action KiOnutrime-CsG is the right ingredient for your business

5 KIONUTRIME-CSG : THE LEADING VEGETAL FAT-BINDER! MECHANISM :

6 KIONUTRIME-CSG : THE LEADING VEGETAL FAT-BINDER! Binds at least 800 times its own weight in fat 33 % more efficient than the other fat-binders!

7 KIONUTRIME-CSG : THE LEADING VEGETAL FAT-BINDER! Faster dissolution (10min)! Lower molecular weight!

8 WHAT ABOUT FORMULATING KIONUTRIME-CSG? Completely ODORLESS and TASTELESS Many galenic forms: TABLETS, CAPSULES, SACHETS:

9 REGULATORY STATUS EUROPEAN UNION: Substantially equivalent to shellfish chitosan according to Novel Food Regulation (EC) 258/97 article 4.3 with regard to: Composition Nutritional value Metabolism European Food Safety Authority (EFSA) 5th batch released late June 2011 Positive evaluation related to chitosan and maintenance of normal blood LDLcholesterol. In weighing the evidence, a meta-analysis of Randomized controlled trials, which investigated the effects of chitosan consumption on blood lipids, has been evaluated by the Panel and showed a statistically significant reduction in total and LDLcholesterol concentrations. 3g of chitosan should be consumed daily.

10 REGULATORY STATUS THE UNITED-STATES: Generally Recognized as Safe (GRAS) pursuant to 21 CFR Section 8(413) (c) of the Dietary Supplement health and Education Act (DSHEA) of 1994 defines a new dietary ingredient as a dietary ingredient that was not marketed in the United States before October 15, Chitosan is listed on the following lists as dietary supplement ingredients use before 94 National Herbal Products Association (NNFA) Council for Responsible Nutrition (CRN) Utah Natural Products Association (UNPA) FDA bioterrorism registration number:

11 KIONUTRIME-CSG ALSO AVAILABLE IN FOOD & BEVERAGE TECHNOLOGY The increased attention for chitosan applications in the food industry is being readily considered due to its several distinctive biological activities and functional properties. THESE INCLUDE ITS ANTIMICROBIAL ACTIVITY AND FILM-FORMING PROPERTY.

12 KIONUTRIME-CSG IN FINISHED PRODUCT As an example, KiOslim is composed of KiOnutrime-CsG

13 Steve BOLOGNE Account Manager Wesley GUERRA Account Manager +32 (0)